Abstract: A combination for administration to a mammal which combination employes a therapeutically effective amount of medicinal and/or therepeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scarr tissue) at the site to be treated, through the cell membrane into the individual cells to be treated.

Abstract: A method is provided of inhibiting the narrowing of the vascular tubular walls of an animal by the proliferation of endothelial cells in the area of trauma after the vascular tubular walls have been traumatized, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof to the animal to inhibit the narrowing of the vascular tubular walls by the proliferation of endothelial cells into the area of trauma.

Abstract: A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology or trauma of skin or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeutically effective non-toxic dosage amount of a drug for the treatment of the disease or condition of the skin or exposed tissue at the site of the pathology or trauma and an effective non-toxic dosage amount of hyaluronic acid or salts thereof or homologues, analogues, derivatives, complexes, esters, fragments, or sub-units of hyaluronic acid to transport the drug to the site of the pathology or trauma of the disease or condition.

Abstract: The invention relates to a method of controlling the unloading of a drug from the skin or exposed tissue of a human into the lymphatic system comprising transporting an effective dosage amount of the drug into the skin or exposed tissue by an effective non-toxic amount of a form of hyaluronic acid.

Abstract: This invention relates to a method of inhibiting the narrowing of the tubular walls of an animal with a form of hyaluronic acid.

Abstract: A dosage amount of a pharmaceutical composition comprising a therapeutically effective amount of an agent to treat a disease or condition involving underperfused tissue and pathological tissue in humans and a form of hyaluronic acid, wherein the form of hyaluronic acid is available to transport the agent from the point of administration to the site to be treated.

Abstract: A method of detoxifying a patient by peritoneal dialysis which patient will benefit from peritoneal dialysis treatment by involving underperfused or pathological tissue the administration of an agent suitable for peritoneal dialysis treatment, comprising administering to the patient a therapeutically effective dosage amount of a pharmaceutical composition for peritoneal dialysis treatment, each dosage amount comprising a therapeutically effective amount of an agent suitable for use in peritoneal dialysis and a sufficient amount of a form of hyaluronic acid selected from hyaluronic acid and non-toxic salts and combinations thereof sufficient to alter the agent's performance in the human body wherein said amount of the form of hyaluronic acid is sufficient to provide a dosage between 10 mg and 3000 mg of the form of hyaluronic acid and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons but greater than 150,000 daltons.

Abstract: A pinless caster assembly comprising a first substantially "T"-shaped part and a second substantially ring-shaped solid part, said first and second parts interfitting with bearing elements and when interfit providing races for the bearing elements and the caster assembly, said first and second part being machined from solid material of predetermined metallurgical characteristics, said first part having disposed therewith a first one-half raceway, for receiving load-carrying bearings in use, and a second one-half raceway for receiving swivel bearings in use, said second part having disposed therewith a third one-half raceway for receiving load-carrying bearings in use for mating with the first one-half raceway disposed with the first part and thereby providing a load-carrying race of the caster assembly, said second part also having disposed therewith a fourth one-half raceway for receiving swivel bearings in use and for mating with the second one-half raceway disposed with the first part and thereby providing

Abstract: Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue of a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue of a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.

Abstract: A method for the treatment of mucous membrane trauma disease or condition for the relief of pain associated therewith comprising administering topically an effective amount of a composition comprising an N.S.A.I.D. and a form of hyaluronic acid selected from hyaluronic acid, pharmaceutically acceptable salts thereof, fragments thereof and/or subunits thereof.

Abstract: The present pump design with the elimination of a separate hydraulic fluid path from the cylinder dramatically improves the efficiency and pressure achieved by the pump by 15% as a result of reducing the number of chambers provided in the pump interior. It is, however, imperative for reasons not completely understood that in order for these efficiencies to be obtained that a reservoir of oil be located adjacent the main oil intake volume to ensure quick filling of the main oil intake volume as the piston cycles to its pressure stroke. This prevents cavitation of the pump.

Abstract: A cartridge for a valve housing having outlets, the cartridge comprising a stationary body sleeve for fixed insertion within the housing and having outlet ports permanently aligned with the outlets of the housing, a moveable substantially hollow stem sleeve inserted within the stationary body sleeve and having an opening selectively alignable with the ports of the stationary body sleeve, the body sleeve and hollow stem being connected to one another by a retaining ring which aligns and maintains the cartridge as a unit in the housing. The diverting valve may be installed as a deck mounted fixture in a tub, whirlpool, soaking bath, spa, roman tub, or the like wherein the tub spout is located below the flood line rim of the respective fixture wherein the diverting valve can be repaired by replacing the cartridge from the top of the valve by removing the handle and replacing the cartridge in its entirety.

Abstract: This invention relates to new stereoselective processes for preparing 3-substituted-4-aryl piperidines and methods for controlling the absolute stereochemistry at the C-3 and C-4 positions of the piperidine ring. Compounds of this type are key intermediates in the preparation of paroxetine, femoxetine, and other medicaments.

Abstract: A pharmaceutical composition is provided comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology and/or trauma of skin and/or exposed tissue of a human patient in need of treatment suffering from a disease or condition. Each such dosage amount comprises a therapeutically effective non-toxic (to the patient) dosage amount of a drug for the treatment of the disease and/or condition of the skin and/or exposed tissue at the site of the pathology and/or trauma and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof to transport (to facilitate or cause the transport of) the drug to the site of the pathology and/or trauma of the disease or condition.

Abstract: A head assembly for a pultrusion process for pultruding pultrudable material is provided. The head assembly includes a floating adjustable assembly carrying a pultrusion die. The die has a center line disposed proximate the center line of the process and an entrance, and an exit. The material passing from the entrance to the exit of the die in forming an acceptable finished shape is maintained when formed with the center line of the exit of the die always remaining stationary and disposed proximate the center line of the process.

Abstract: A closure assembly includes a track and a slidable and pivotable closure member. The closure member is engaged with the track proximate first and second pivots adjacent the pivotable end of the member, the first and second pivots being interconnected by a multiple segment shaft (for example at least two portions) (for example telescoping) which provides for accurate installation, retention, removal, adjustment and alignment of the first and second pivots in a substantially parallel line for pivotally supporting the closure member so that it may be safely and securely pivoted away from the closure assembly.

Abstract: Topically applied transdermally quick penetrating compositions containing a drug and hyaluronic acid and/or salts thereof and methods of treating diseases and conditions employing said compositions.

Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.